The company is an industry-leading integrated biomedical R&D service platform, providing innovative R&D solutions spanning the full cycle for the global pharmaceutical and medical device industry. Through a comprehensive service system and top quality standards, we help the biomedical industry improve R&D efficiency, reduce R&D risks, ensure high-quality delivery of research projects, accelerate the marketization process of pharmaceutical products, and fulfill our promises to the industry and patients. The company is a contract research organization (CRO) focusing on providing professional services throughout the clinical trial process for new drug research and development. It provides comprehensive and comprehensive clinical research solutions for global pharmaceutical and medical device innovators, ensures research quality, reduces R&D risks, shortens R&D cycles, saves R&D expenses, and promotes the product marketization process, so that patients can use newer and better pharmaceuticals and medical products as soon as possible. The services provided by the company mainly include clinical trial technical services and clinical trial-related services and laboratory services. Corporate honors: Eli Lilly Global Supplier Award, MSD Supplier Outstanding Service Award, Top 10 Listed Chinese Pharmaceutical Companies with the Most Investment Value, etc.
相关临床试验
5
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
进行中（未招募）
1
20.0%
尚未招募
2
40.0%
招募中
1
20.0%
Unknown
1
20.0%
暂无批准数据
- HCW Biologics and WY Biotech have formed Beijing Trimmune Biotech, securing initial funding from CITIC Medical Fund and TigerMed to develop the cancer immunotherapy HCW11-006. - The joint venture involves a $7 million deal structure, with Trimmune holding exclusive worldwide licensing rights for HCW11-006 and planning Phase 1 trials in China for solid tumors by first half 2027. - HCW Biologics retains a royalty-free option to reclaim development rights for the Americas territory after Phase 1 completion, while receiving milestone payments and double-digit royalties on future sales.
- Angel Pharmaceuticals received IND approval from China's NMPA to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis treatment. - The randomized, double-blinded, placebo-controlled trial will evaluate multiple dosing regimens over 12 weeks, with patient enrollment expected to begin in Q3 2025. - Soquelitinib is an investigational oral ITK inhibitor developed by Corvus Pharmaceuticals, representing a novel immunotherapy approach for immune diseases. - Phase 1b data is anticipated in 2026, while Corvus continues parallel development in the U.S. with plans for a Phase 2 trial by year-end.
- Teddy Laboratory, a subsidiary of Tigermed, has signed a strategic cooperation agreement with LabConnect to build a full-chain laboratory service system covering China and international markets. - The partnership establishes Teddy Laboratory as LabConnect's preferred laboratory partner in China, while LabConnect becomes Teddy's preferred central lab partner for overseas operations. - The collaboration creates a complementary "China-based capabilities + global service network" model to accelerate innovative drug development and commercialization worldwide. - Both companies will leverage their respective strengths to enhance global clinical trial service standards and support multinational pharmaceutical companies in expanding their operations.
- Medidata and Tigermed have extended their long-standing partnership to enhance clinical trial processes from early-phase studies to post-marketing surveillance through advanced cloud-based solutions. - Tigermed has successfully conducted over 300 therapeutic trials using the Medidata Platform since 2011, demonstrating proven effectiveness in improving trial efficiency and data-driven decision making. - The expanded collaboration will integrate Medidata AI technology and automated data capture capabilities to streamline clinical trial workflows and accelerate treatment delivery globally.
